Beilu Pharma(SZ:300016) 智通财经网·2025-12-25 07:59Core Viewpoint - Beilu Pharmaceutical has received approval from the National Medical Products Administration for the registration certificate of Sildenafil Citrate Orally Disintegrating Tablets, which is a significant development for the company in the erectile dysfunction treatment market [1] Company Summary - Beilu Pharmaceutical (300016.SZ) has announced the receipt of a drug registration certificate for Sildenafil Citrate Orally Disintegrating Tablets from the National Medical Products Administration [1] - Sildenafil is a selective phosphodiesterase type 5 inhibitor used for treating erectile dysfunction, known for its rapid onset and effective results [1] - The orally disintegrating tablet form of Sildenafil, developed by Pfizer, was approved for import in China in 2019, indicating a strategic move to enhance product offerings in the market [1] Industry Summary - The Sildenafil Citrate Orally Disintegrating Tablets provide a convenient and discreet option for patients, as they dissolve in the mouth without the need for water and have a quick onset of action [1] - This product addresses the growing demand for flexible and diverse oral medication options among patients suffering from erectile dysfunction [1]